Skip to content
DataLookout
Menu

NCT03223610

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 401 versions: 5 with changes below, 45 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 1, 2026 to Aug 12, 2027
    • Study completion pushed from Dec 1, 2027 to Dec 12, 2029
  2. New version filed on ClinicalTrials.gov
  3. Minor Enrollment target: 145 to 155v374
  4. Study Status, Study Descriptionv373
  5. Notable Primary completion date: Dec 1, 2025 to Dec 1, 2026
    • Study completion date: Dec 1, 2026 to Dec 1, 2027
    v363
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number and grade of adverse events
Timeframe: 22 days

Secondary (3)

Progression-free survival (PFS)
Overall survival (OS)
Overall response rate (ORR)

Arms and interventions

Arm 1: Dose EscalationExperimental

iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6

Arm 2: Dose EscalationExperimental

ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6

Arm 3: Dose ExpansionExperimental

ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6

Arm 4: Dose ExpansionExperimental

iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6

Drugs: Venetoclax, Ibrutinib, Prednisone, Revlimid (lenalidomide)

Biologicals: Obinutuzumab

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States